Home›Trial›NCT05111015
NCT05111015RECRUITING

Tracking Results of Ablations to Combat AF Registry Generation 2

Study Summary

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

Conditions
Atrial Fibrillation
Interventions / Drugs
Open Concomitant Surgical Ablation ProceduresHybrid (Convergent) Ablation ProceduresAtriCure Hybrid Totally Thoracoscopic Ablation ProceduresAtriCure LAA Exclusion Procedures
View on ClinicalTrials.gov ↗
Sponsor
ATRC
AtriCure Inc
Cardiac Surgery
D36/100
Study Details
Enrollment10000 participants
Primary Completion—
Lead SponsorAtriCure, Inc.
Data Retrieved2026-04-11 02:55:07.545203+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 10,000 participants
Sponsor Catalyst Profile

AtriCure Inc (ATRC) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ATRC Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.